RECORD // Company

Akebia Therapeutics, Inc.

Built 2026-11-22T00:02:38Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (13)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

6 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001517022-26-000084

ItemValuePeriodFormFiledAccessionReport
Revenue$36,903,0003 months ended 2026-09-3010-Q2026-11-050001517022-26-0000842026-11-22 00:02 UTCReport an error
Net income (loss)$-14,354,0003 months ended 2026-09-3010-Q2026-11-050001517022-26-0000842026-11-22 00:02 UTCReport an error
Cash and cash equivalents$159,254,000at 2026-09-3010-Q2026-11-050001517022-26-0000842026-11-22 00:02 UTCReport an error
Contract liabilities, current$4,958,000at 2026-09-3010-Q2026-11-050001517022-26-0000842026-11-22 00:02 UTCReport an error
Debt due in the next 12 months$50,558,000at 2026-09-3010-Q2026-11-050001517022-26-0000842026-11-22 00:02 UTCReport an error
Debt due in year 2$1,881,000at 2026-09-3010-Q2026-11-050001517022-26-0000842026-11-22 00:02 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001517022
Ticker
AKBA
EIN
208756903
CUSIP
00972D105
Record ID
sx:sec:0001517022

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

47 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 00:02 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 00:02 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 00:02 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 00:02 UTCReport an error
Business address180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 024512026-11-16SEC EDGAR company profile2026-11-22 00:02 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 00:02 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$236,196,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 00:02 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-5,345,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:02 UTCReport an error
Total assets (at 2025-12-31)$376,565,0002025-12-3110-K, XBRL Assets2026-11-22 00:02 UTCReport an error
Stockholders' equity (at 2025-12-31)$32,610,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:02 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$184,844,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:02 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$67,992,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:02 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$291,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:02 UTCReport an error
Long-term debt (at 2025-12-31)$48,250,0002025-12-3110-K, XBRL LongTermDebt2026-11-22 00:02 UTCReport an error
Operating lease liabilities (at 2025-12-31)$3,548,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:02 UTCReport an error
Form D total offering amount (D/A filed 2011-04-21)$22,101,9552011-04-21D/A2026-11-22 00:02 UTCReport an error
Form D total amount sold (D/A filed 2011-04-21)$13,945,3402011-04-21D/A2026-11-22 00:02 UTCReport an error
Form D industry groupBiotechnology2011-04-21D/A2026-11-22 00:02 UTCReport an error
Form D revenue rangeDecline to Disclose2011-04-21D/A2026-11-22 00:02 UTCReport an error
Form D date of first sale2011-04-062011-04-21D/A2026-11-22 00:02 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-11-16)Entry into Symbiotic Term Loan Facility On November 12, 2026 (the “Closing Date”), Akebia Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) by and among the Company, as borrower representative, certain subsidiaries of the Company from time to time party thereto as a borrower or a guarantor (together with the Company, the “Loan Parties”), Symbiotic Capital Opportunities Holding, L.P. (together with such other lenders from time to time party thereto, the “Lenders”), and Symbiotic Capital Agency LLC, as administrative agent and collateral agent for the Lenders (in such capacities, the “Agent”). The Loan Agreement provides for a senior secured…2026-11-16SEC EDGAR 8-K 0001517022-26-000089 (text as filed, excerpt)2026-11-22 00:02 UTCReport an error
8-K Item 1.02, Termination of a Material Definitive Agreement (filed 2026-11-16)Termination of Kreos Term Loan Facility On January 29, 2024, the Company entered into an Agreement for the Provision of a Loan Facility (as amended, restated, amended and restated, supplemented or otherwise modified, the “Prior Loan Agreement”), by and among the Company and Kreos Capital VII (UK) Limited, as lender representative (“Kreos”), which are funds and accounts managed by BlackRock Inc. In connection with the entry into the Loan Agreement, on the Closing Date, the Prior Loan Agreement and the other loan documents associated therewith were terminated, the payment and other obligations of the Company under the Prior Loan Agreement were paid in full and discharged, and Kreos’ security…2026-11-16SEC EDGAR 8-K 0001517022-26-000089 (text as filed, excerpt)2026-11-22 00:02 UTCReport an error
8-K Item 2.03, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (filed 2026-11-16)The information set forth under Item 1.01 of this Report is incorporated by reference into this Item 2.03.2026-11-16SEC EDGAR 8-K 0001517022-26-000089 (text as filed, excerpt)2026-11-22 00:02 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-11-16)The information set forth under Item 1.01 of this Report with respect to the warrants is incorporated by reference into this Item 3.02.2026-11-16SEC EDGAR 8-K 0001517022-26-000089 (text as filed, excerpt)2026-11-22 00:02 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-16)On November 16, 2026, the Company issued a press release announcing the execution of the Loan Agreement. A copy of the press release is attached as Exhibit 99.1 to this Report. The information in this Item 7.01 of this Report, including the press release attached hereto as Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such a filing.2026-11-16SEC EDGAR 8-K 0001517022-26-000089 (text as filed, excerpt)2026-11-22 00:02 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-16)In connection with the Company's repayment in full of the Prior Loan Agreement, the Company reaffirms that it believes its existing cash resources and the cash it expects to generate from product, royalty, supply and license revenues are sufficient to fund its current operating plan for at least two years. Cautionary Note Regarding Forward Looking Statements This Report contains forward-looking statements of the Company that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Report are forward-looking statements. The words “anticipate,” “believe,” “build,” “can,” “contemplate,” “continue,” “could,” “should,” “designed,”…2026-11-16SEC EDGAR 8-K 0001517022-26-000089 (text as filed, excerpt)2026-11-22 00:02 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-05)On November 5, 2026, Akebia Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026 and recent business highlights. A copy of the Company’s press release containing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K (“Report”) and is incorporated herein by reference. The information in this Report (including Item 2.02 and Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing…2026-11-05SEC EDGAR 8-K 0001517022-26-000083 (text as filed, excerpt)2026-11-22 00:02 UTCReport an error
8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (filed 2026-10-23)On October 21, 2026, Akebia Therapeutics, Inc. (the “Company”) received a deficiency letter (the "Notice") from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.00001 per share (the “Common Stock”), had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no immediate effect on the listing of the Company’s Common Stock. In accordance with Nasdaq Listing Rule…2026-10-23SEC EDGAR 8-K 0001517022-26-000075 (text as filed, excerpt)2026-11-22 00:02 UTCReport an error
Employer name (as filed)Akebia Therapeutics, Inc.2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:02 UTCReport an error
Certified LCAs12026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:02 UTCReport an error
Certified LCAs later withdrawn02026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:02 UTCReport an error
Total worker positions on certified LCAs12026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:02 UTCReport an error
Top job titles (title, LCA count)Senior Specialist, Regulatory Affairs (1)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:02 UTCReport an error
Wage offered, annualized (n, min, median, max)median $118,431 (range $118,431-$118,431, 1 filings)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:02 UTCReport an error
Worksite statesWA2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-22 00:02 UTCReport an error
Plan (pension, plan no. 001)AKEBIA THERAPEUTICS 401(K) PLAN: 397 participants, assets $52,470,1532025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 00:02 UTCReport an error
Plan (welfare, plan no. 501)AKEBIA THERAPEUTICS, INC. HEALTH & WELFARE BENEFITS PLAN: 188 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 00:02 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$22,784,4662026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:02 UTCReport an error
Largest institutional holder #2 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$12,907,2432026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:02 UTCReport an error
Largest institutional holder #3 (13F as filed): AQR CAPITAL MANAGEMENT LLC$10,432,7372026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:02 UTCReport an error
Largest institutional holder #4 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$7,671,1482026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:02 UTCReport an error
Largest institutional holder #5 (13F as filed): STATE STREET CORP$6,145,5722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:02 UTCReport an error
Largest institutional holder #6 (13F as filed): JACOBS LEVY EQUITY MANAGEMENT, INC$4,871,2502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:02 UTCReport an error
Largest institutional holder #7 (13F as filed): Nantahala Capital Management, LLC$4,560,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:02 UTCReport an error
Largest institutional holder #8 (13F as filed): GOLDMAN SACHS GROUP INC$4,205,6502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:02 UTCReport an error
Largest institutional holder #9 (13F as filed): MILLENNIUM MANAGEMENT LLC$3,644,1302026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:02 UTCReport an error
Largest institutional holder #10 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$2,888,7342026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:02 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.